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Are associational studies
obfuscating?
To the Editor: We at the Medical Technology and Prac-
tice Patterns Institute (MTPPI) have serious concerns re-
garding the recently published article by Li and Collins
[1]. Namely, while the authors repeatedly acknowledge
that the significant associations found in their study do
not infer a causal relationship, they inexplicably disre-
gard the results of the two randomized clinical trials that
do in fact establish causality. Specifically, the authors do
not resolve the contradictions between their associational
study findings and the clinical trial results of Besarab et al
[2] or Furuland et al [3]. In the former, although not sta-
tistically significant, higher rates of both hospitalization
and mortality were found among the cohort randomized
to a normal hematocrit of 0.42 versus 0.30. In the latter
Swedish study, which the authors do not mention, there
were no significant differences in morbidity or mortality
based on the randomized target cohorts. It is noteworthy
that both Besarab and Furuland also found an associ-
ation between increased hematocrit and improved sur-
vival; however, these findings were contradicted by the
causal results based on the randomization scheme. The
associational results reported by Li and Collins there-
fore are at odds with the extant clinical trial evidence and
therefore must be relegated to a lower heirarchy of proof.
In our opinion, associational studies such as this one only
muddy the waters and provide little clarity as to the true
causal pathways. At best, such studies are obfuscating;
at worst, they are misleading and potentially harmful.
Given the growing concern regarding the cardiovascular-
associated complications related to epoetin therapy, the
Li and Collins study provides no new information for this
debate. We conclude by reiterating the authors’ own con-
clusion, “a randomized clinical trial . . . is needed.”
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Reply from the Authors
We thank Dr. Thamer for her comments on our paper
[1].
For us, the study by Besarab et al [2] was a starting
point. They found that hemodialysis patients with heart
disease in whom epoetin was used to raise the hemat-
ocrit value to 42% had a nearly statistically significant
increased risk of death or nonfatal myocardial infarction
(compared with those whose hematocrit value was main-
tained at 30%) and halted their prospective investigation.
We decided to use a retrospective analysis to discover
actual outcomes in patients with hematocrit values of
>36% to ≤39% and >39%. These values are of interest
to us for their approximate correspondence to the target
hemoglobin values given in the National Kidney Foun-
dation’s Dialysis Outcomes Quality Initiative guidelines
[3]. As stated in our paper, we found these patients to
be at significantly lower risk of hospitalization and death,
findings consistent with previous findings by our group
[4].
It is not entirely clear how to apply the findings of
Besarab et al [2] for our purposes. One could infer that
patients are better served with hematocrit values of 30%
rather than 42%. Were this the case, patients who initiate
dialysis with hemoglobin values of 10 g/dL (or hemat-
ocrit values of 30%) would fare worse over time with
higher hematocrit values than they have in the past. In
fact, observational federal data do not support this. The
mortality of patients with the shortest time on dialysis has
decreased significantly during the past 10 years, as it has in
those on dialysis for two to five years; the only patients
with higher mortality over time are those on dialysis for
more than five years [5]. The Besarab data do not seem to
support an argument for maintaining hematocrit values
at 30% in the types of patients studied.
Regarding the study by Furuland et al [6], we re-
spectfully suggest that this study was not adequately
powered to convincingly demonstrate a mortality ad-
vantage or disadvantage associated with hemoglobin
level.
Space limitations do not allow a broad defense of the
value of observational studies. They allow investigation
of large populations to identify associations and gener-
ate hypotheses for use in prospective, randomized tri-
als. They also allow assessment of the real practice of
medicine across large and diverse patient populations.
Randomized clinical trials are necessarily restricted to
select populations. The magnitude of the effect demon-
strated in a randomized trial is often far less than that
observed in a general clinical population because of the
presence of confounding factors that cannot be controlled
in routine practice. Therefore, observational studies and
randomized clinical trials play complimentary roles. Fi-
nally, observational studies allow the investigation of
issues that cannot otherwise be studied, or that could be
